Page last updated: 2024-11-13

dinophysistoxin 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dinophysistoxin 2: structure given in first source; a principal toxin responsible for diarrhetic shellfish poisoning [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dinophysistoxin 2 : A ketal that is a rare marine toxin structurally related to okadaic acid. Found yearly along with okadaic acid in Portuguese shellfish, its presence has been correlated with the occurrence of Dinophysis acta. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID91800179
CHEBI ID145981
MeSH IDM0205073

Synonyms (18)

Synonym
dinophysistoxin 2
dtx2
(2r)-2-hydroxy-3-[(2s,5r,6r,8s)-5-hydroxy-8-{(2r,3e)-4-[(2r,4a'r,5r,6's,8'r,8a's)-8'-hydroxy-6'-{(1s,3s)-1-hydroxy-3-[(2s,6r,11r)-11-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl}-7'-methyleneoctahydro-3h,3'h-spiro[furan-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3
139933-46-3
dinophysistoxin-2
dtx 2
(2r)-3-[(2s,5r,6r,8s)-8-{(2r,3e)-4-[(2r,4'ar,5r,6's,8'r,8'as)-8'-hydroxy-6'-{(1s,3s)-1-hydroxy-3-[(2s,6r,11r)-11-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl}-7'-methylidenehexahydro-3'h-spiro[oxolane-2,2'-pyrano[3,2-b]pyran]-5-yl]but-3-en-2-yl}-5-hydroxy
CHEBI:145981
dtx-2
unii-rh78dhy1jz
rh78dhy1jz ,
1,7-dioxaspiro(5.5)undec-10-ene-2-propanoic acid, alpha,5-dihydroxy-alpha,10-dimethyl-8-((1r,2e)-1-methyl-3-((2r,4'ar,5r,6's,8'r,8'as)-octahydro-8'-hydroxy-6'-((1s,3s)-1-hydroxy-3-((2s,6s,11r)-11-methyl-1,7-dioxaspiro(5.5)undec-2-yl)butyl)-7'-methylenespi
acanthifolicin, 9,10-deepithio-9,10-didehydro-31-demethyl-35-methyl-, (35r)-
(35r)-9,45-seco-10-demercapto-9,10-didehydro-35-methyl-39-noracanthifolicin
j531.104g ,
(2r)-3-[(2s,6r,8s,11r)-2-[(e,2r)-4-[(2s,2'r,4r,4as,6r,8ar)-4-hydroxy-2-[(1s,3s)-1-hydroxy-3-[(2s,6r,11r)-11-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]butyl]-3-methylidenespiro[4a,7,8,8a-tetrahydro-4h-pyrano[3,2-b]pyran-6,5'-oxolane]-2'-yl]but-3-en-2-yl]-11-h
DTXSID50893702
Q27288119

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In accordance with the response surface design model, the LD50 for DTX-2 and OA was 338 and 206 microg/kg, respectively."( Relative toxicity of dinophysistoxin-2 (DTX-2) compared with okadaic acid, based on acute intraperitoneal toxicity in mice.
Aasen, JA; Aune, T; Hess, P; Larsen, S; Rehmann, N; Satake, M, 2007
)
0.34
" Recent studies indicate that DTX-2 is about half as toxic and has about half the affinity for protein phosphatase 2A (PP2A) as OA."( A structural basis for the reduced toxicity of dinophysistoxin-2.
Arcus, V; Cox, NR; Huhn, J; Jeffrey, PD; Larsen, K; Miles, CO; Rise, F; Rundberget, T; Shi, Y, 2009
)
0.35
" Studies carried out in mice indicated that DSP poisonous are toxic towards experimental animals with a lethal oral dose 2-10 times higher than the intraperitoneal (i."( Experimental basis for the high oral toxicity of dinophysistoxin 1: a comparative study of DSP.
Botana, LM; Fernández, DA; Fraga, M; Louzao, MC; Vieytes, MR; Vilariño, N, 2014
)
0.4
" DTX-1 displayed the most toxic effect in the three tested cell lines."( Evaluation of okadaic acid, dinophysistoxin-1 and dinophysistoxin-2 toxicity on Neuro-2a, NG108-15 and MCF-7 cell lines.
Diogène, J; Soliño, L; Sureda, FX, 2015
)
0.42
" They had different toxicokinetics and toxic potency."( Toxic Action Reevaluation of Okadaic Acid, Dinophysistoxin-1 and Dinophysistoxin-2: Toxicity Equivalency Factors Based on the Oral Toxicity Study.
Abal, P; Botana, AM; Botana, LM; Carrera, C; Louzao, MC; Suzuki, T; Vieytes, MR; Vilariño, N; Watanabe, R, 2018
)
0.48
" Results confirmed that DTX1 is more toxic than OA by oral route while DTX2 is less toxic."( Toxic Action Reevaluation of Okadaic Acid, Dinophysistoxin-1 and Dinophysistoxin-2: Toxicity Equivalency Factors Based on the Oral Toxicity Study.
Abal, P; Botana, AM; Botana, LM; Carrera, C; Louzao, MC; Suzuki, T; Vieytes, MR; Vilariño, N; Watanabe, R, 2018
)
0.48
" However, recent in vitro studies indicated that DTX-1 seems to be more toxic than OA."( Benchmark dose analyses of γH2AX and pH3 endpoints for quantitative comparison of in vitro genotoxicity potential of lipophilic phycotoxins.
Fessard, V; Le Hegarat, L; Roudot, AC, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
toxinPoisonous substance produced by a biological organism such as a microbe, animal or plant.
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitorAny EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ketalAn acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (15.07)18.2507
2000's24 (32.88)29.6817
2010's30 (41.10)24.3611
2020's8 (10.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.39 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.30%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (98.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]